MBI Med Biogene Inc

Med BioGene Inc. (TSX VENTURE:MBI) today announced that its board of directors
(the "Board") has adopted an Advance Notice Policy (the "Policy"). The purpose
of the Policy is to provide shareholders, directors and management of MBI with a
clear framework for nominating directors of MBI at a shareholders' meeting. MBI
is committed to: (i) facilitating an orderly and efficient annual general or,
where the need arises, special meeting, process; (ii) ensuring that all
shareholders receive adequate notice of the director nominations and sufficient
information regarding all director nominees; and (iii) allowing shareholders to
register an informed vote after having been afforded reasonable time for
appropriate deliberation. The Policy is intended to further these objectives and
is in effect as of the date of this press release.


The Policy, among other things, includes a provision that requires advance
notice to MBI in certain circumstances where nominations of persons for election
to the Board are made by shareholders of MBI. The Policy fixes a deadline by
which director nominations must be submitted to MBI prior to any annual or
special meeting of shareholders and sets forth the information that must be
included in the notice to MBI. No person will be eligible for election as a
director of MBI unless nominated in accordance with the Policy.


In the case of an annual meeting of shareholders, notice to MBI must be made not
less than 30 days and not more than 65 days prior to the date of the annual
meeting; provided, however, that, in the event that the annual meeting is to be
held on a date that is less than 50 days after the date on which the first
public announcement of the date of the annual meeting was made, notice may be
made not later than the close of business on the 10th day following such public
announcement.


In the case of a special meeting of shareholders called for the purpose of
electing directors (whether or not called for other purposes), notice to MBI
must be made not later than the close of business on the 15th day following the
day on which the first public announcement of the date of the special meeting
was made.


Notwithstanding the above timelines for advance notice, in the case of the
annual and special meeting of shareholders of the Company to be held on May 17,
2013, notice to MBI must be made no later than the close of business on April
30, 2013.


The full text of the Policy is available under MBI's profile at www.sedar.com or
upon request by contacting MBI's Chief Financial Officer, Scott Davis, at 1
(800) 641-3593.


About Med BioGene Inc.

Med BioGene is a life science company based in Vancouver, British Columbia that
is currently focused on managing the license and rights to GeneFx(R) Lung. Med
BioGene's common shares are listed for trading on the TSX Venture Exchange. For
more information, please visit www.medbiogene.com.


About GeneFx Lung

GeneFx Lung is a proprietary gene expression-based test to improve upon staging
for identifying those patients with early-stage non-small-cell lung cancer
(NSCLC) who, following surgical removal of their tumor, are at higher and lower
risks of mortality. In an initial study of patient specimens from the National
Cancer Institute of Canada Clinical Trials Group JBR.10 trial, published in the
Journal of Clinical Oncology, patients classified by GeneFx Lung as higher risk
benefited from adjuvant chemotherapy, and those classified as lower risk did not
benefit and may have experienced a detrimental effect from adjuvant
chemotherapy. GeneFx Lung was subsequently validated in predicting patient
mortality in four independent studies involving data from tumor specimens
totaling 676 untreated early-stage NSCLC patients. GeneFx Lung is expected to
provide better-informed and personalized treatment decisions to assist in the
selection of patients for adjuvant chemotherapy.


On April 15, 2011, Precision Therapeutics, Inc. and Med BioGene closed their
commercialization agreement. The agreement provides to Precision exclusive
global rights to develop and commercialize GeneFx Lung.


Precision expects to commence commercialization of GeneFx Lung through its
CLIA-certified laboratory by mid-2013.


About Precision Therapeutics, Inc.

Precision, a leading life science company based in Pittsburgh, Pennsylvania, is
dedicated to improving the outcomes of cancer patients by providing personalized
medicine solutions that aim to increase quality of life and cancer survival
rates. Precision offers a portfolio of products developed to help guide
physicians and patients with difficult clinical decisions throughout the cancer
care continuum. For more information, please visit
www.precisiontherapeutics.com.


Certain information in this press release contains forward-looking information
and statements ("forward-looking information") of MBI under applicable Canadian
and United States legislation. Words such as "anticipates," "believes,"
"estimates," "expects," "intends," "may," "plans," "projects," "will," "would"
and similar expressions are intended to identify forward-looking information,
although not all forward-looking information contains these identifying words.
Forward looking information includes, but is not limited to, that with respect
to the timing, completion and/or results of clinical trials or studies, the
timing for commercialization of any products, future profits, future product
revenues, future shareholder value, future operations and plans, the completion
and use of proceeds from transactions or financings and the prospects for
negotiating partnerships or collaborations and their timing. This
forward-looking information is only a prediction based upon MBI's current
expectations, and actual events or results may differ materially. MBI may not
actually achieve the plans, intentions or expectations disclosed in its
forward-looking information. Forward-looking information is subject to known and
unknown risks and uncertainties and is based upon uncertain assumptions that
could cause a MBI's actual results and the timing of events to differ materially
from those anticipated in such forward-looking information. You are cautioned
not to place undue reliance on this forward-looking information, which speak
only as of the date of this press release. MBI's forward-looking information
does not reflect the potential impact of any future partnerships,
collaborations, acquisitions, mergers, dispositions, joint ventures or
investments that MBI may make. All forward-looking information herein is
qualified in its entirety by this cautionary statement and MBI undertakes no
obligation to revise or update any such forward-looking information as a result
of new information, future events or otherwise after the date of this press
release, other than as required by applicable law. Certain information included
in this press release in respect of Precision and its scientific, clinical and/
or commercialization efforts and expectations have been provided to MBI by
Precision. MBI may not have been able to confirm the accuracy of such
information and you should not place undue reliance on any such information,
including any information regarding Precision that may constitute
forward-looking information. A redacted copy of the commercialization agreement
between MBI and Precision may be found at www.sedar.com. Each trademark, trade
name or service mark of any entity appearing in this press release belongs to
its holder.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Med BioGene Inc.
Erinn B. Broshko
Executive Chairman
(800) 641-3593
ebroshko@medbiogene.com
www.medbiogene.com

Med Biogene (TSXV:MBI)
Historical Stock Chart
From Apr 2024 to May 2024

Med Biogene (TSXV:MBI)
Historical Stock Chart
From May 2023 to May 2024